South Korea
· Delayed Price · Currency is KRW Kangstem Biotech Statistics
Total Valuation
Kangstem Biotech has a market cap or net worth of KRW 78.81 billion. The enterprise value is 56.22 billion.
| Market Cap | 78.81B |
| Enterprise Value | 56.22B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Kangstem Biotech has 56.05 million shares outstanding. The number of shares has increased by 31.71% in one year.
| Shares Outstanding | 56.05M |
| Shares Change (YoY) | +31.71% |
| Shares Change (QoQ) | -2.91% |
| Owned by Insiders (%) | 5.94% |
| Owned by Institutions (%) | 0.16% |
| Float | 44.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.25 |
| PB Ratio | 1.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.76 |
| EV / Sales | 4.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.26 |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 14.88.
| Current Ratio | 3.09 |
| Quick Ratio | 2.44 |
| Debt / Equity | 14.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -23.70 |
Financial Efficiency
Return on equity (ROE) is -25.70% and return on invested capital (ROIC) is -23.01%.
| Return on Equity (ROE) | -25.70% |
| Return on Assets (ROA) | -18.75% |
| Return on Capital (ROIC) | -23.01% |
| Revenue Per Employee | 136.88M |
| Profits Per Employee | -100.67M |
| Employee Count | 97 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 13.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.58% |
| 50-Day Moving Average | 1,725.28 |
| 200-Day Moving Average | 2,144.59 |
| Relative Strength Index (RSI) | 42.77 |
| Average Volume (20 Days) | 360,743 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kangstem Biotech had revenue of KRW 13.28 billion and -9.76 billion in losses. Loss per share was -196.85.
| Revenue | 13.28B |
| Gross Profit | 1.89B |
| Operating Income | -20.79B |
| Pretax Income | -11.80B |
| Net Income | -9.76B |
| EBITDA | -17.05B |
| EBIT | -20.79B |
| Loss Per Share | -196.85 |
Balance Sheet
The company has 30.26 billion in cash and 7.66 billion in debt, giving a net cash position of 22.59 billion or 403.07 per share.
| Cash & Cash Equivalents | 30.26B |
| Total Debt | 7.66B |
| Net Cash | 22.59B |
| Net Cash Per Share | 403.07 |
| Equity (Book Value) | 51.49B |
| Book Value Per Share | 918.56 |
| Working Capital | 26.91B |
Cash Flow
In the last 12 months, operating cash flow was -15.78 billion and capital expenditures -1.45 billion, giving a free cash flow of -17.23 billion.
| Operating Cash Flow | -15.78B |
| Capital Expenditures | -1.45B |
| Free Cash Flow | -17.23B |
| FCF Per Share | -307.36 |
Margins
Gross margin is 14.22%, with operating and profit margins of -156.55% and -73.54%.
| Gross Margin | 14.22% |
| Operating Margin | -156.55% |
| Pretax Margin | -88.90% |
| Profit Margin | -73.54% |
| EBITDA Margin | -128.41% |
| EBIT Margin | -156.55% |
| FCF Margin | -129.76% |
Dividends & Yields
Kangstem Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.71% |
| Shareholder Yield | -31.71% |
| Earnings Yield | -14.00% |
| FCF Yield | -21.86% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |